Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
While semaglutide targets only GLP-1 receptors, tirzepatide is a dual agonist that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, adding a second metabolic pathway to the mechanism
It has been identified in plasma and other tissues, and is thought to play a role in processes related to repair and regeneration
Clinical trial evidence: An analysis of several clinical trials for weight loss, people taking semaglutide 2.4 mg had similar rates of anxiety and other mental health issues as those taking a placebo
Thats likely down to its triple-action formula, which combines GLP-1, GIP, and glucagon receptors, previously unheard of in other weight loss treatments
US$ 27.21
US$ 21.21
US$ 22.78
